Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of allogeneic mesenchymal stem cell therapy in patients with hypophosphatasia
jRCT1060210038Recruiting
- Sponsor
- Shimane University
- Start
- Oct 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of MSV alogénicas in hypophosphatasia (HPP), sponsored by Shimane University. Started Oct 2021; status: recruiting.
02
Drugs
MSV alogénicas
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on jRCT1060210038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1060210038.